How to Get Finasteride in Utah

At a glance
- Telehealth Rx allowed / Yes, Utah law permits telehealth prescribing of finasteride
- Standard doses / 1 mg daily (androgenetic alopecia), 5 mg daily (BPH)
- Typical time to prescription / 24 to 48 hours after intake visit
- Lab work required / PSA recommended before starting; testosterone panel optional
- Utah Medicaid coverage / Not covered for male pattern hair loss; BPH coverage varies by plan
- 503A compounding / Licensed Utah 503A pharmacies may dispense compounded finasteride
- Who can prescribe / MD, DO, NP, PA all authorized under Utah scope-of-practice law
- Prior authorization / Rarely required for cash-pay telehealth; may apply to commercial insurance
- Prescription transfer / Yes, finasteride transfers freely between Utah pharmacies
- Manufacturer options / Brand Propecia (Merck), generic finasteride, and 503A compounded forms
What Is Finasteride and Why Do Utah Men Use It?
Finasteride is a type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for miniaturizing scalp follicles in androgenetic alopecia (AGA) and for driving prostate enlargement in benign prostatic hyperplasia (BPH). The FDA first approved the 5 mg tablet (Proscar) for BPH in 1992 and the 1 mg tablet (Propecia) for male pattern hair loss in 1997 [1].
The key two-year trial by Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553) found that finasteride 1 mg daily produced a statistically significant increase in hair count versus placebo at both vertex and anterior mid-scalp regions, with 83% of treated men maintaining or increasing hair count at 24 months compared with 28% on placebo [2]. A separate Phase III program (N=1,879) demonstrated that finasteride 5 mg reduced prostate volume by a mean of 18% and improved International Prostate Symptom Score by 3.3 points versus placebo over 4 years [3].
DHT suppression begins within 24 hours of the first dose. Serum DHT falls approximately 65% with the 1 mg dose and approximately 70% with the 5 mg dose [4]. Visible hair retention typically takes 3 to 6 months, and peak cosmetic benefit is generally observed at 12 months of continuous therapy [2].
How to Get a Finasteride Prescription in Utah
Utah residents have three practical pathways to a finasteride prescription: an in-person dermatologist or urologist visit, a primary care appointment, or a licensed telehealth platform. Telehealth is the most common route today because it removes scheduling delays and geography from the equation.
In-person care. A board-certified dermatologist or urologist can diagnose AGA or BPH, assess PSA levels, and issue a written or electronic prescription during a single visit. Wait times at Utah academic centers (University of Utah Health, Intermountain Healthcare) range from 2 to 6 weeks for a new-patient appointment.
Primary care. Family medicine physicians and internists in Utah routinely prescribe finasteride for both indications. The American Academy of Family Physicians recognizes finasteride as a first-line pharmacologic option for AGA [5].
Telehealth. Utah Code Ann. § 26-60-102 defines telehealth broadly and permits a valid prescriber-patient relationship to be established through synchronous audio-video, asynchronous store-and-forward evaluation, or a combination of both [6]. A licensed Utah telehealth provider may issue a finasteride prescription after completing a clinical intake that includes medical history, symptom review, and, for BPH cases, a prostate symptom score questionnaire.
Most telehealth platforms use a four-step process: (1) complete an online intake form covering relevant medical history, current medications, and symptom timeline; (2) upload a photograph of scalp hair or provide a symptom score for BPH; (3) conduct a brief synchronous or asynchronous clinical review with the prescribing clinician; (4) receive an e-prescription sent electronically to a pharmacy of your choice. Total elapsed time from intake form submission to prescription approval typically runs 4 to 24 hours on business days [6].
What Labs Are Needed Before Starting Finasteride in Utah?
A PSA measurement before starting finasteride is clinically standard for men over 40, and the FDA label specifically recommends establishing a baseline PSA [1]. Finasteride reduces PSA by approximately 50% after 6 months of use, meaning clinicians must double the on-treatment PSA value to interpret it correctly relative to population norms [7].
For men under 40 seeking finasteride solely for AGA, many Utah telehealth providers accept a detailed symptom history without mandatory lab work, particularly when no urinary symptoms or family history of prostate cancer is reported. The American Urological Association (AUA) guideline on early detection of prostate cancer advises PSA screening discussions beginning at age 40 for average-risk men and at age 40 for men with a family history of prostate cancer [8].
A full testosterone panel is not required before prescribing finasteride for hair loss, though it may be ordered to rule out secondary causes of hair shedding such as hypogonadism or thyroid dysfunction. A CBC and comprehensive metabolic panel are not routinely required by Utah prescribers for finasteride initiation [9].
Recommended pre-treatment lab checklist for Utah clinicians, per the Endocrine Society and AUA guidance:
- PSA (men 40 and older, or any age with urinary symptoms)
- Total testosterone if concomitant hypogonadism is suspected [10]
- TSH if diffuse hair loss pattern suggests thyroid etiology [9]
- Hepatic function panel only if significant liver disease history exists, as finasteride undergoes hepatic metabolism [1]
Who Can Prescribe Finasteride in Utah?
Utah grants prescribing authority to MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) within their respective scopes of practice. The Utah Division of Occupational and Professional Licensing (DOPL) licenses all four categories, and all four may legally issue a finasteride prescription for an appropriate indication [6].
NPs in Utah practice under the Advanced Practice Registered Nurse (APRN) framework. Since 2019, Utah has granted full practice authority to APRNs, meaning NPs do not require a physician collaboration agreement to prescribe Schedule-exempt medications such as finasteride [6]. PAs must maintain a supervision agreement with a collaborating physician, though prescribing of non-controlled substances like finasteride falls well within standard PA scope [11].
Dermatologists remain the most common specialists for AGA prescriptions. Urologists manage the majority of BPH cases. Primary care physicians, NPs, and PAs represent the largest combined prescriber group for finasteride in community settings, and telehealth NPs and PAs account for a growing share of new finasteride starts nationally [5].
Telehealth Providers in Utah Prescribing Finasteride
Licensed telehealth platforms operating in Utah must hold a valid Utah prescriber license (for any clinician who signs prescriptions) and must comply with the Utah Telehealth Act. Platforms that prescribe controlled substances face additional DEA registration requirements, but finasteride is not a controlled substance, so those restrictions do not apply [6].
When evaluating a telehealth provider, confirm the following before submitting payment:
- The prescribing clinician holds an active Utah license verifiable through the DOPL license lookup tool.
- The platform performs a genuine clinical evaluation rather than a checkbox questionnaire with automatic approval.
- The pharmacy partner is licensed by the Utah Department of Commerce, Division of Occupational and Professional Licensing, or is an accredited out-of-state mail-order pharmacy registered to operate in Utah.
- The platform's privacy practices comply with HIPAA.
HealthRX operates as a licensed telehealth provider in Utah. Clinicians on the HealthRX medical team review each intake, may request a synchronous video visit for complex cases, and issue e-prescriptions to partner pharmacies capable of same-day dispensing or two-day shipping throughout Utah.
Finasteride Pharmacies in Utah: Retail, Mail-Order, and 503A Compounding
Retail pharmacies. Generic finasteride 1 mg and 5 mg tablets are stocked at essentially every major Utah retail pharmacy chain, including Smith's (Kroger), Harmons, Costco, Walgreens, and CVS locations across Salt Lake City, Provo, Ogden, St. George, and Logan. A 30-day supply of generic finasteride 1 mg typically costs $15 to $35 without insurance and $5 to $15 with a GoodRx coupon at Utah retail locations [12].
Mail-order pharmacies. Accredited mail-order pharmacies registered to ship into Utah may dispense a 90-day supply, which reduces per-unit cost and improves adherence. The FDA does not restrict mail-order dispensing of finasteride as a non-controlled substance [1].
503A compounding pharmacies. Utah-licensed 503A compounding pharmacies may prepare finasteride in alternative dose forms (topical solution, combination formulations) when a prescriber documents a specific clinical rationale for compounding. The FDA distinguishes 503A pharmacies (patient-specific prescriptions) from 503B outsourcing facilities; both categories operate in Utah [13]. Compounded finasteride is not FDA-approved as a finished drug product, and patients should confirm that any Utah 503A pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or an equivalent body [13].
The National Association of Boards of Pharmacy (NABP) maintains a database of verified internet pharmacies (VIPPS program). Checking NABP status before ordering from an online pharmacy reduces the risk of receiving counterfeit or subpotent product [14].
Transferring an Existing Finasteride Prescription to Utah
Finasteride is a non-controlled legend drug. Utah pharmacy law allows pharmacies to accept transferred prescriptions for non-controlled substances without restriction on the number of transfers, provided refills remain on the original prescription [15]. A new-to-Utah patient may call any Utah retail or mail-order pharmacy, provide the name and phone number of the originating pharmacy, and the receiving pharmacist will complete the transfer directly.
If the original prescription is exhausted or expired, the patient will need a new prescription issued by a Utah-licensed prescriber or by an out-of-state telehealth prescriber who holds a valid Utah license and has established a compliant prescriber-patient relationship under Utah's telehealth statute [6].
Insurance plans sometimes require the prescriber's NPI number to match their network directory. Patients transferring coverage from another state should confirm that their Utah insurer recognizes the prescribing clinician or seek a new prescription from an in-network Utah provider to avoid claim rejection.
Utah Medicaid and Insurance Coverage for Finasteride
Utah Medicaid does not cover finasteride for androgenetic alopecia, classifying the indication as cosmetic. Coverage for the 5 mg BPH indication under Utah Medicaid is plan-specific and subject to prior authorization in most managed care organizations [16].
Commercial insurance coverage varies widely. Some plans cover generic finasteride 5 mg for BPH under a Tier 1 or Tier 2 formulary position with a $0 to $10 copay. The 1 mg AGA formulation is frequently excluded from commercial formularies as a lifestyle drug. Patients should verify formulary status through their insurer's drug lookup tool before filling.
Prior authorization for finasteride BPH coverage under Utah commercial plans typically requires:
- Documentation of AUA Symptom Score of 8 or higher [8]
- Evidence of at least one prior trial of an alpha-blocker (e.g., tamsulosin 0.4 mg daily for 4 to 8 weeks) unless contraindicated
- PSA result and prostate volume estimate if available from imaging
The Affordable Care Act does not mandate coverage of finasteride for either indication, so out-of-pocket cash-pay pricing through discount programs remains a practical option for most Utah patients [17].
Side Effects and Monitoring After Starting Finasteride in Utah
Finasteride's most discussed adverse effects are sexual in nature. The product label reports decreased libido in 1.8% of treated men, erectile dysfunction in 1.3%, and ejaculation disorder in 1.2% at the 1 mg dose versus 1.3%, 0.7%, and 0.8% on placebo, respectively, in the 12-month controlled trial [1]. These rates are low in absolute terms, though a subset of patients report persistent symptoms after discontinuation, a phenomenon described in the published literature as post-finasteride syndrome [18].
The FDA added a label update in 2012 noting reports of persistent sexual side effects after discontinuation and, separately, reports of depression and suicidal ideation [1]. Utah prescribers are expected to counsel patients on these risks before initiating therapy.
Monitoring during treatment should include:
- PSA recheck at 6 months (remember to double the measured value for clinical interpretation) [7]
- Annual PSA thereafter for men over 40 [8]
- Blood pressure and cardiovascular history review if combination therapy with an alpha-blocker is planned for BPH [3]
- Symptom check at 3 months to assess sexual function and mood, per standard clinical practice [9]
Finasteride is FDA Pregnancy Category X (teratogenic in male fetuses). Crushed or broken tablets should not be handled by women who are or may become pregnant [1]. Utah pharmacists are required to dispense finasteride in child-resistant packaging and may attach an auxiliary label regarding pregnancy risk [15].
The PCPT (Prostate Cancer Prevention Trial, N=18,882) found that finasteride 5 mg daily over 7 years reduced the overall period prevalence of prostate cancer by 24.8% (P<0.001) but was associated with a higher rate of high-grade (Gleason score 7 to 10) tumors in the treated arm (6.4% vs. 5.1%) [19]. The FDA reviewed this data and concluded in 2011 that the label should reflect the high-grade tumor signal, though subsequent analyses suggest the finding may reflect detection bias from improved PSA sensitivity under finasteride rather than true carcinogenesis [19].
Getting Started: Step-by-Step for Utah Residents
- Decide on indication. Hair loss (1 mg daily) and BPH (5 mg daily) follow separate diagnostic pathways. Have your symptom timeline ready.
- Order baseline labs if you are 40 or older. A PSA drawn before your first dose gives the treating clinician a clean baseline [7].
- Choose your access point. In-person appointment, primary care, or telehealth. For telehealth, confirm the clinician holds an active Utah license at dopl.utah.gov.
- Complete the clinical intake honestly. Disclose all current medications, particularly 5-alpha-reductase inhibitors, alpha-blockers, or any hormone therapy already in use.
- Receive your e-prescription. Most Utah telehealth platforms transmit the prescription to your chosen pharmacy within 4 to 24 hours of clinical approval.
- Fill your prescription. Use a licensed Utah retail pharmacy, a VIPPS-verified mail-order pharmacy, or a PCAB-accredited 503A compounder if your prescriber has specified a compounded form [14].
- Set a 6-month PSA reminder. Enter a calendar reminder for the 6-month mark so you and your clinician can recheck PSA with proper interpretation [7].
- Reassess hair or urinary symptom response at 12 months. Finasteride for AGA requires at least 12 months of continuous therapy before a fair efficacy assessment can be made [2].
Frequently asked questions
›How do I get a finasteride prescription in Utah?
›What labs are needed before starting finasteride in Utah?
›Are there telehealth providers in Utah prescribing finasteride?
›How long until I receive finasteride in Utah?
›Can I transfer a finasteride prescription to Utah?
›Are 503A pharmacies in Utah licensed to ship finasteride?
›Who can prescribe finasteride in Utah: MD vs NP vs PA?
›What documentation does prior authorization require in Utah?
References
- U.S. Food and Drug Administration. Propecia (finasteride) 1 mg tablet prescribing information. Merck & Co. Accessed January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563. https://pubmed.ncbi.nlm.nih.gov/9475762/
- Vermeulen A, Giagulli VA, De Schepper P, et al. Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha-reductase in humans. Prostate. 1989;14(1):45-53. https://pubmed.ncbi.nlm.nih.gov/2538917/
- American Academy of Family Physicians. Androgenetic alopecia clinical practice guidelines. AAFP. Accessed January 2025. https://www.aafp.org/pubs/afp/issues/2023/0600/androgenetic-alopecia.html
- Utah Code Ann. § 26-60-102. Utah Telehealth Act. Utah Legislature. Accessed January 2025. https://le.utah.gov/xcode/Title26/Chapter60/26-60-S102.html
- Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. J Urol. 1994;151(5):1283-1290. https://pubmed.ncbi.nlm.nih.gov/7512659/
- American Urological Association. Early detection of prostate cancer: AUA guideline 2023. https://www.auanet.org/guidelines-and-quality/guidelines/prostate-cancer-early-detection-guideline
- Endocrine Society. Androgen deficiency syndromes in men: clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. https://pubmed.ncbi.nlm.nih.gov/20525905/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- American Academy of Physician Associates. PA scope of practice. AAPA. Accessed January 2025. https://www.aapa.org/practice-resources/clinical-practice-resources/
- GoodRx. Finasteride prices and coupons. Accessed January 2025. https://www.goodrx.com/finasteride
- U.S. Food and Drug Administration. Compounding: 503A vs 503B. FDA. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/503a-503b
- National Association of Boards of Pharmacy. VIPPS accreditation program. NABP. Accessed January 2025. https://nabp.pharmacy/programs/vipps/
- Utah Administrative Code R156-17b. Utah Pharmacy Practice Act. Utah Division of Occupational and Professional Licensing. Accessed January 2025. https://rules.utah.gov/publicat/code/r156/r156-17b.htm
- Utah Department of Health and Human Services. Utah Medicaid preferred drug list. Accessed January 2025. https://medicaid.utah.gov/pharmacy/
- U.S. Centers for Medicare and Medicaid Services. Affordable Care Act preventive services coverage. CMS. Accessed January 2025. https://www.cms.gov/cciio/resources/data-resources/aca-preventive-services
- Traish AM, Mulgaonkar A, Giordano N. The dark side of 5-alpha-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367-379. https://pubmed.ncbi.nlm.nih.gov/24955228/
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. https://pubmed.ncbi.nlm.nih.gov/12824459/